Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 251 to 300 of 8163 results

  1. Flow transcranial direct current stimulation for treating depression (MIB324)

    NICE has developed a medtech innovation briefing (MIB) on Flow transcranial direct current stimulation for treating depression .

  2. Indicator advisory committee members

    Biographies and interests register for the indicator advisory committee

  3. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  4. Executive team

    Biographies of the NICE executive team and minutes of their meetings

  5. NICE launches refreshed support service for life sciences industry

    NICE has launched its refreshed support service for the life sciences sector, NICE Advice.

  6. Board committees

    Our board has 2 sub-committees: the audit and risk committee and the remuneration committee . Audit and risk committee The audit and risk committee

  7. Listening to the system - implementing virtual wards

    Angela sets out to understand some of the challenges, benefits and considerations of setting up and running a virtual ward, from the perspective of teams on the front lines.

  8. Early access to medicines scheme (EAMS)

    A joint NICE and NHS England meeting can help to ensure you're ready for NHS patient access and subsequent NICE appraisal

  9. Models for the evaluation and purchase of antimicrobials

    Antimicrobial resistance (AMR) is an urgent global challenge. It causes around 700,000 deaths each year globally . That number is predicted to rise to

  10. Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.

  11. Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

  12. Pneumonia in adults: diagnosis and management (CG191)

    This guideline was developed before the COVID-19 pandemic. It covers diagnosing and managing pneumonia in adults who do not have COVID-19. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment.

  13. Jaundice in newborn babies under 28 days (CG98)

    This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.

  14. NICE launches first modular update to its methods and processes

    NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of updating recommendations on COVID-19 treatments.

  15. NICE health technology evaluations: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website.

  16. Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) (QS210)

    This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.

  17. The proportion of women aged 50-70 years whose record shows a breast screening test has been performed within the last 3 years

    The proportion of women aged 50-70 years whose record shows a breast screening test has been performed within the last 3 years Subject(s):

  18. The percentage of patients on the learning disability register, who: received a learning disability health check and had a completed health action plan in the preceding 12 months and, have a recording of ethnicity

    The percentage of patients on the learning disability register, who: received a learning disability health check and had a completed health action...

  19. The percentage of urgent suspected colorectal cancer referrals accompanied by a faecal immunochemical test (FIT) result, with the result recorded in the twenty-one days leading up to the referral

    The percentage of urgent suspected colorectal cancer referrals accompanied by a faecal immunochemical test (FIT) result, with the result recorded in...

  20. The percentage of patients on the learning disability register who received a learning disability health check and had a completed health action plan in the preceding 12 months

    The percentage of patients on the learning disability register who received a learning disability health check and had a completed health action plan...

  21. The proportion of invasive cases of cancer diagnosed via an emergency route

    The proportion of invasive cases of cancer diagnosed via an emergency route Subject(s): Cancer

  22. The proportion of eligible people aged 60-74 years whose record shows a bowel screening test has been performed within the last 2.5 years

    The proportion of eligible people aged 60-74 years whose record shows a bowel screening test has been performed within the last 2.5 years

  23. Executive team meetings

    NICE executive team meeting minutes and agenda

  24. Technology appraisal processes

    We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.

  25. First NICE-recommended treatment for Parkinson's set to benefit hundreds

    Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).

  26. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

  27. Evidence standards framework (ESF) for digital health technologies

    NICE standards for innovators of digital health technologies and NHS commissioners

  28. Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)

    Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.

  29. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  30. Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

    Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.

  31. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

  32. Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions (IPG774)

    Evidence-based recommendations on vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. This involves removing the uterus (womb), and sometimes the fallopian tubes and ovaries, through the vagina.

  33. Charging procedure: technology appraisal and highly specialised technologies evaluations

    Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly

  34. Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)

    NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA923

  35. People who have had a stroke should be offered additional rehabilitation to help them recover NICE says in updated guidance

    People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover, NICE has said in updated guidance published today.

  36. Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (IPG773)

    Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.

  37. Stroke rehabilitation in adults (NG236)

    This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.

  38. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  39. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

  40. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

  41. Daridorexant for treating long-term insomnia (TA922)

    Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.

  42. Proportion of people with stroke who receive joint health and social care plans on discharge from hospital

    Proportion of people with stroke who receive joint health and social care plans on discharge from hospital Subject(s): Stroke and

  43. The proportion of people who had a stroke who are reviewed within 6 months of being admitted to hospital

    The proportion of people who had a stroke who are reviewed within 6 months of being admitted to hospital Subject(s): Stroke and ischaemic

  44. The proportion of people who had a stroke that are supported by a skilled stroke early supported discharge (ESD) team

    The proportion of people who had a stroke that are supported by a skilled stroke early supported discharge (ESD) team Subject(s):

  45. First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK

    More than 700 people set to benefit from new treatment option for advanced lymphoma.

  46. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  47. Seven technologies recommended to help people with non-specific low back pain

    People with low back pain could be offered apps to help them manage their condition after seven digital technologies were recommended by NICE in draft guidance.

  48. Public board meetings

    Wednesday 19 July 2023 at 1:30pm via Zoom. Agenda Apologies for absence To receive any apologies for absence. Declarations of interest To

  49. Social care trainers' resource

    Training resources for those working in social care

  50. Virtual ward platform technologies for acute respiratory infections (HTE13)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections....